MIRA PHARMACEUTICALS, INC. - 8-K Filing Summary
Business Context and Reporting Period
This Form 8-K Current Report, dated September 11, 2026, details the results of MIRA Pharmaceuticals, Inc.'s 2026 Annual Meeting of Stockholders. The Company is incorporated in Florida and its common stock trades on The Nasdaq Capital Market under the symbol "MIRA". The record date for the meeting was July 21, 2026.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes rather than financial performance.
Material Changes and Voting Results
Three proposals were submitted to stockholders, and all were approved. A total of 26,499,076 shares (approximately 63.06% of outstanding shares) were present or represented by proxy, constituting a quorum.
- Proposal 1 (Election of Directors): Stockholders elected five directors: Erez Aminov, Matthew Whalen, Matthew Del Giudice, M.D., Denil Nanji Shekhat, M.D., and Edward MacPherson. All nominees received significant majority support, with "Votes For" ranging from approximately 20.1 million to 20.6 million shares.
- Proposal 2 (Ratification of Auditors): Stockholders ratified the appointment of Salberg & Company, P.A. as the independent registered public accounting firm for the fiscal year ending December 31, 2026. The vote was 25,950,852 For, 158,064 Against, and 390,160 Abstained.
- Proposal 3 (Adjournment): Stockholders approved a proposal to adjourn the meeting if necessary to solicit additional proxies. The vote was 24,897,741 For, 1,205,307 Against, and 396,028 Abstained.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management commentary on financial outlook, specific risks, contingencies, or unusual items. The document serves strictly as a disclosure of the Annual Meeting results.
Key Facts for Investor Verification
- Verify the full composition of the newly elected Board of Directors and their tenure terms.
- Confirm the engagement of Salberg & Company, P.A. as the independent auditor for the 2026 fiscal year.
- Review the definitive proxy statement filed on July 28, 2026, for detailed background on the proposals and director nominees.
- Note that 5,713,034 broker non-votes were recorded for the director election, indicating shares held by brokers that were not voted on that specific proposal.